Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gastrointestinal Applications of Iodine Quantification Using Dual-Energy CT: A Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Self-Collected versus Healthcare Worker-Collected Swabs in the Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa) undergoing primary ADT was predictive of the development of CRPC and PCa-specific mortality. The study included 191 patients who commenced ADT from 2000 to 2011. The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low expression. The risks of CRPC and PCa-specific mortality were analyzed using stratified cumulative incidences and a cause-specific COX regression analysis for competing risk assessment. The median follow-up time was 9.8 (IQR: 6.1-12.7) years. In total, 94 and 97 patients presented with low and high AZGP1 expression, respectively. A low AZGP1 expression was found to be associated with a shorter time to CRPC when compared to patients with a high AZGP1 expression (HR: 1.5; 95% CI: 1.0-2.1; p = 0.03). However, the multivariable analysis demonstrated no added benefit by adding the AZGP1 expression to prediction models for CRPC. No differences for PCa-specific mortality between the AZGP1 groups were observed. In conclusion, a low AZGP1 expression was associated with a shorter time to CRPC for PCa patients treated with first-line ADT but did not add any predictive information besides well-established clinicopathological variables.

Original languageEnglish
Article number520
JournalDiagnostics
Volume10
Issue number8
ISSN2075-4418
DOIs
Publication statusPublished - Aug 2020

    Research areas

  • Androgen deprivation therapy, AZGP1, Biomarker, Prostate cancer

ID: 60879479